Epigenomics Regains Rights for Tamoxifen
Treatment Response Test from Roche

Epigenomics has regained full rights to a tamoxifen treatment response test from Roche Diagnostics, the company said this week.

Epigenomics, which is focused on developing tests based on DNA methylation, said that it will now handle the full development of the test itself.

The tissue-based test is designed to predict the probability of disease recurrence in breast cancer patients, and was part of a multi-product collaboration with Roche Diagnostics, Epigenomics said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.